Portal de Periódicos da CAPES

Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers

2009; American Society for Microbiology; Volume: 83; Issue: 22 Linguagem: Inglês

10.1128/jvi.01005-09

1098-5514

Yo Hoshino, Harutaka Katano, Ping Zou, Patricia Hohman, Adriana Marques, Stephen K. Tyring, Dean Follmann, Jeffrey I. Cohen,

Parvovirus B19 Infection Studies

ABSTRACT Epstein-Barr virus (EBV) establishes a latent infection in B cells in the blood, and the latent EBV load in healthy individuals is generally stable over time, maintaining a “set point.” It is unknown if the EBV load changes after long-term antiviral therapy in healthy individuals. We treated volunteers with either valacyclovir (valaciclovir) or no antiviral therapy for 1 year and measured the amount of EBV DNA in B cells every 3 months with a novel, highly sensitive assay. The number of EBV-infected B cells decreased in subjects receiving valacyclovir (half-life of 11 months; P = 0.02) but not in controls (half-life of 31 years; P = 0.86). The difference in the slopes of the lines for the number of EBV-infected B cells over time for the valacyclovir group versus the control group approached significance ( P = 0.054). In contrast, the number of EBV DNA copies per B cell remained unchanged in both groups ( P = 0.62 and P = 0.92 for the control and valacyclovir groups, respectively). Valacyclovir reduces the frequency of EBV-infected B cells when administered over a long period and, in theory, might allow eradication of EBV from the body if reinfection does not occur.